Facebook, flu vaccines and more—News of Note by Eric Sagonowsky Wednesday, February 20, 2019 Here is some other vaccine news of note for the week.
AstraZeneca, Pfizer Japan and more—FiercePharmaAsia by Angus Liu Friday, February 15, 2019 AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.
Novavax's NanoFlu bests Sanofi's Fluzone HD in seniors by Eric Sagonowsky Wednesday, January 9, 2019 Novavax's NanoFlu vaccine beat Sanofi's Fluzone HD in seniors in a midstage test, setting up the smaller company's shot for a move into phase 3.
Drone deliveries, HIV vaccines and more—News of Note by Eric Sagonowsky Wednesday, December 19, 2018 Here is some other vaccine news of note for the week.
Flu vaccination rates better so far this season: CDC by Eric Sagonowsky Tuesday, December 18, 2018 After a horrible flu season last year, more people have gotten vaccinations so far this year, according to the CDC.
Why China's flu vaccine supply is suffering this season by Angus Liu Wednesday, November 28, 2018 The number of flu shots that passed Chinese regulators so far this season has fallen about 19%, leaving the country short on needed supplies.
J&J opens €72M vaccine plant for stepped-up R&D by Eric Sagonowsky Thursday, October 25, 2018 Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing capacity has to measure up.
Roche’s Tamiflu successor, Xofluza, wins fast FDA nod by Angus Liu Thursday, October 25, 2018 Roche hopes the single-dose flu drug can squeeze out some generic competition to Tamiflu.
Altimmune, Ebola outbreak and more—News of Note by Eric Sagonowsky Wednesday, October 24, 2018 Here is some other vaccine news of note for the week.
Seqirus' cell-based Flucelvax nears first-ever EU approval by Eric Sagonowsky Tuesday, October 23, 2018 While Seqirus works to boost manufacturing for its cell-based flu vaccine in the U.S., the shot is nearing an approval in Europe.
